The USFDA has issued final approval to manufacture and market Aurobindo Pharma's diabetes drugs, Pioglitazone tablets and Pioglitazone Hydrochloride + Metformin Hydrochloride tablets.
Pioglitazone Tablets USP 15mg, 30mg & 45mg and Pioglitazone Hydrochloride + Metformin Hydrochloride Tablets, 15mg (base)/500mg & 15mg(base)/850mg are ready for launch.
Both the products are indicated for type-2 diabetes mellitus treatment as an added therapy with diet and exercise to improve glycemic control in adults.
Pioglitazone tablets USP 15mg, 30mg, 45mg are the generic equivalents to Takeda Global Research Development Center's Actos tablets 15mg, 30mg, 45mg.
Pioglitazone Hydrochloride + Metformin Hydrochloride Tablets, 15mg(base)/500mg, 15mg(base)/850mg are the generic equivalents of Takeda Global Research Development Center's Actoplus Met tablets, 15mg (base)/500mg, 15mg (base)/850mg.
